FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4312129148> ?p ?o ?g. }

• W4312129148 abstract "111In[In]-BnDTPA-trastuzumab-NLS is a radiopharmaceutical with theranostic applications for imaging and Meitner-Auger electron (MAE) radioimmunotherapy (RIT) of HER2-positive breast cancer (BC). Nuclear localization sequence (NLS) peptides route the radiopharmaceutical to the nucleus of HER2-positive BC cells following receptor-mediated internalization for RIT with subcellular range MAEs. The γ-photons emitted by 111In permit tumour imaging by SPECT. Our aim was to formulate a kit under Good Manufacturing Practices conditions to prepare 111In[In]-BnDTPA-trastuzumab-NLS injection for a first-in-human clinical trial.Trastuzumab was derivatized with p-SCN-BnDTPA to introduce Bn-DTPA for complexing 111In, then modified with maleimide groups for conjugation to the thiol on cysteine in NLS peptides [CGYGPKKKRKVGG]. BnDTPA-trastuzumab-NLS (5 mg in 1.0 mL of 0.05 M ammonium acetate buffer, pH 5.5) was dispensed into unit dose sterile glass vials to produce kits for labeling with 100-165 MBq of 111In[In]Cl3. The kits met specifications for protein concentration (4.5-5.5 mg/mL), volume (0.95-1.05 mL), pH (5.5-6.0), appearance (clear, pale-yellow, particulate-free), BnDTPA substitution level (2.0-7.0 BnDTPA/trastuzumab), purity and homogeneity (SDS-PAGE and SE-HPLC), 111In labeling efficiency (> 90%), binding to HER2-positive SK-BR-3 human breast cancer cells (Ka = 1-8 × 108 L/mmol; Bmax = 0.5-2 × 106 sites/cell), NLS peptide conjugation (upward band shift on SDS-PAGE), sterility (USP Sterility Test) and endotoxins (USP Bacterial Endotoxins Test). 111In-BnDTPA-trastuzumab-NLS injection met specifications for pH (5.5-6.5), radiochemical purity (≥ 90%), radionuclide purity (≥ 99%), appearance (clear, colourless, particle-free) and sterility (retrospective USP Sterility Test). Kits were stable stored at 2-8 °C for up to 661 days (d) meeting all key specifications. Protein concentration remained within or just slightly greater than the specification for up to 139 d. 111In[In]-BnDTPA-trastuzumab-NLS injection was stable for up to 24 h. An expiry of 180 d was assigned for the kits and 8 h for the final radiopharmaceutical.A kit was formulated under GMP conditions for preparing 111In[In]-BnDTPA-trastuzumab-NLS injection. This radiopharmaceutical was safely administered to 4 patients with HER2-positive BC to trace the uptake of trastuzumab into brain metastases before and after MRI-guided focused ultrasound (MRIg-FUS) by SPECT imaging." @default.
• W4312129148 created "2023-01-04" @default.
• W4312129148 creator A5023465589 @default.
• W4312129148 creator A5027315167 @default.
• W4312129148 creator A5051836274 @default.
• W4312129148 creator A5069657541 @default.
• W4312129148 date "2022-12-21" @default.
• W4312129148 modified "2023-09-25" @default.
• W4312129148 title "Formulation of a kit under Good Manufacturing Practices (GMP) for preparing [111In]In-BnDTPA-trastuzumab-NLS injection: a theranostic agent for imaging and Meitner-Auger Electron (MAE) radioimmunotherapy of HER2-positive breast cancer" @default.
• W4312129148 cites W1533229981 @default.
• W4312129148 cites W1639752340 @default.
• W4312129148 cites W1972058890 @default.
• W4312129148 cites W2005907891 @default.
• W4312129148 cites W2021997973 @default.
• W4312129148 cites W2040371382 @default.
• W4312129148 cites W2045869644 @default.
• W4312129148 cites W2092014058 @default.
• W4312129148 cites W2092695916 @default.
• W4312129148 cites W2110444464 @default.
• W4312129148 cites W2121058401 @default.
• W4312129148 cites W2128314339 @default.
• W4312129148 cites W2137076998 @default.
• W4312129148 cites W2137228442 @default.
• W4312129148 cites W2141917836 @default.
• W4312129148 cites W2151595238 @default.
• W4312129148 cites W2153565541 @default.
• W4312129148 cites W2159967578 @default.
• W4312129148 cites W2160499123 @default.
• W4312129148 cites W2165308087 @default.
• W4312129148 cites W2190063129 @default.
• W4312129148 cites W2218133630 @default.
• W4312129148 cites W2339810454 @default.
• W4312129148 cites W2402322861 @default.
• W4312129148 cites W2553761594 @default.
• W4312129148 cites W2979722259 @default.
• W4312129148 cites W2995808512 @default.
• W4312129148 cites W3011983932 @default.
• W4312129148 cites W3052318948 @default.
• W4312129148 cites W312950801 @default.
• W4312129148 cites W3142072058 @default.
• W4312129148 cites W3165734744 @default.
• W4312129148 cites W3207084414 @default.
• W4312129148 cites W4283586318 @default.
• W4312129148 doi "https://doi.org/10.1186/s41181-022-00186-9" @default.
• W4312129148 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36542157" @default.
• W4312129148 hasPublicationYear "2022" @default.
• W4312129148 type Work @default.
• W4312129148 citedByCount "0" @default.
• W4312129148 crossrefType "journal-article" @default.
• W4312129148 hasAuthorship W4312129148A5023465589 @default.
• W4312129148 hasAuthorship W4312129148A5027315167 @default.
• W4312129148 hasAuthorship W4312129148A5051836274 @default.
• W4312129148 hasAuthorship W4312129148A5069657541 @default.
• W4312129148 hasBestOaLocation W43121291481 @default.
• W4312129148 hasConcept C121608353 @default.
• W4312129148 hasConcept C126322002 @default.
• W4312129148 hasConcept C159654299 @default.
• W4312129148 hasConcept C178790620 @default.
• W4312129148 hasConcept C185592680 @default.
• W4312129148 hasConcept C186435350 @default.
• W4312129148 hasConcept C190062978 @default.
• W4312129148 hasConcept C197404232 @default.
• W4312129148 hasConcept C203014093 @default.
• W4312129148 hasConcept C2776146153 @default.
• W4312129148 hasConcept C2779786085 @default.
• W4312129148 hasConcept C2779931791 @default.
• W4312129148 hasConcept C2989005 @default.
• W4312129148 hasConcept C2993559085 @default.
• W4312129148 hasConcept C49805395 @default.
• W4312129148 hasConcept C530470458 @default.
• W4312129148 hasConcept C542903549 @default.
• W4312129148 hasConcept C55493867 @default.
• W4312129148 hasConcept C71924100 @default.
• W4312129148 hasConceptScore W4312129148C121608353 @default.
• W4312129148 hasConceptScore W4312129148C126322002 @default.
• W4312129148 hasConceptScore W4312129148C159654299 @default.
• W4312129148 hasConceptScore W4312129148C178790620 @default.
• W4312129148 hasConceptScore W4312129148C185592680 @default.
• W4312129148 hasConceptScore W4312129148C186435350 @default.
• W4312129148 hasConceptScore W4312129148C190062978 @default.
• W4312129148 hasConceptScore W4312129148C197404232 @default.
• W4312129148 hasConceptScore W4312129148C203014093 @default.
• W4312129148 hasConceptScore W4312129148C2776146153 @default.
• W4312129148 hasConceptScore W4312129148C2779786085 @default.
• W4312129148 hasConceptScore W4312129148C2779931791 @default.
• W4312129148 hasConceptScore W4312129148C2989005 @default.
• W4312129148 hasConceptScore W4312129148C2993559085 @default.
• W4312129148 hasConceptScore W4312129148C49805395 @default.
• W4312129148 hasConceptScore W4312129148C530470458 @default.
• W4312129148 hasConceptScore W4312129148C542903549 @default.
• W4312129148 hasConceptScore W4312129148C55493867 @default.
• W4312129148 hasConceptScore W4312129148C71924100 @default.
• W4312129148 hasFunder F4320320118 @default.
• W4312129148 hasFunder F4320334506 @default.
• W4312129148 hasIssue "1" @default.
• W4312129148 hasLocation W43121291481 @default.
• W4312129148 hasLocation W43121291482 @default.
• W4312129148 hasLocation W43121291483 @default.
• W4312129148 hasLocation W43121291484 @default.
• W4312129148 hasOpenAccess W4312129148 @default.

• next